Level of circulating dsDNA and response to therapy for TA-TMA. (A) Levels of dsDNA were significantly elevated 4 weeks into therapy compared with prior to therapy (P = .006), and 2 weeks into therapy in the cohort of patients with TA-TMA (P = .0006). Following resolution of TA-TMA and discontinuation of therapy, levels dropped significantly compared with 4 weeks into therapy (P < .0001) and prior to therapy (P = .04). (B) In the cohort of patients with TA-TMA (N = 18), those who also had GVHD (N = 7) prior to the initiation of therapy had significantly higher levels of dsDNA compared with those without GVHD (N = 11). (C) In the same cohort of patients with TA-TMA (N = 18), those with GVHD following resolution of TA-TMA and discontinuation of therapy (N = 6) had significantly higher levels of dsDNA compared with those without GVHD (N = 12). Tx, therapy.